Price T Rowe Associates Inc Arbutus Biopharma Corp Transaction History
Price T Rowe Associates Inc
- $867 Billion
- Q4 2024
A detailed history of Price T Rowe Associates Inc transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Price T Rowe Associates Inc holds 56,452 shares of ABUS stock, worth $185,162. This represents 0.0% of its overall portfolio holdings.
Number of Shares
56,452
Previous 47,804
18.09%
Holding current value
$185,162
Previous $185,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding ABUS
# of Institutions
165Shares Held
102MCall Options Held
649KPut Options Held
666K-
Morgan Stanley New York, NY22.6MShares$74.1 Million0.01% of portfolio
-
Whitefort Capital Management, LP New York, NY13.2MShares$43.4 Million22.74% of portfolio
-
Black Rock Inc. New York, NY11.6MShares$37.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.98MShares$29.5 Million0.0% of portfolio
-
Two Seas Capital LP Rye, NY8.74MShares$28.7 Million4.68% of portfolio
About Arbutus Biopharma Corp
- Ticker ABUS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 149,951,008
- Market Cap $492M
- Description
- Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...